Clinical Trial

T2 Biomarkers Predictive Value in Occupational Asthma After Cessation of Exposure.

Study acronym: EAPT2
Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
Because of the negative results reported in other studies
Summary
Occupational exposure is known to cause 15% of asthma cases. The main treatment for occupational asthma is to stop exposure if possible. Although, remission of occupational asthma only occurs in only 30 % of patients after cessation of exposure. There is currently no way of predicting which patients will go into remission after cessation of exposure. In non-occupational asthma, the inflammatory biomarker T2 has allowed the entry into personalized medicine and can predict future exacerbations. The investigators hypothesize that T2 biomarkers could be predictive markers for remission in occupational asthma after exposure cessation. The investigators intend to carry out a follow-up study at the University Hospital of Strasbourg to perform the non-specific bronchial hyperresponsiveness test to assess remission in patients diagnosed with occupational asthma and to compare baseline T2 biomarkers in remission and non remission patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-27.
Status change: Not Yet Recruiting → Withdrawn 2026-06-18
Trial Details
NCT Number NCT07006285
Lead Sponsor University Hospital, Strasbourg, France
Conditions Asthma, Occupational Asthma, Occupational Diseases
Start Date 2025-06
Primary Completion 2025-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-23